Verition Fund Management LLC Cytek Biosciences, Inc. Transaction History
Verition Fund Management LLC
- $17.4 Billion
- Q3 2024
A detailed history of Verition Fund Management LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 37,942 shares of CTKB stock, worth $258,764. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,942
Previous 13,757
175.8%
Holding current value
$258,764
Previous $76,000
176.32%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CTKB
# of Institutions
133Shares Held
71.6MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$116 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$80.3 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$64.7 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$45.4 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$28.4 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $918M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...